Furthermore, Va-CLs-based delivery platforms appear to be potential novel nanocarriers for RNA delivery to VCAM-1 overexpression sites, providing new options for miRNA delivery and cardiovascular disease treatment. Here, VCAM1 is linked to cardiovascular disorder.